[关键词]
[摘要]
帕金森病是一种常见的神经系统退行性疾病,多发于60岁以上老年人。发病机制为中脑黑质多巴胺能神经元发生变性进而死亡,从而进一步导致纹状体多巴胺含量显著减少而致病。匹莫范色林(pimavanserin)是由美国阿卡迪亚制药(ACADIA Pharmaceuticals)开发的抗帕金森精神病的新药,为5-羟色胺2A受体(5-HT2A)的强力选择性抑制剂,主要用于幻觉和错觉等帕金森精神病症状的治疗。综述匹莫范色林的化学性质、药理作用、临床试验、不良反应等研究情况。
[Key word]
[Abstract]
Parkinson's disease is a common degenerative disease of the nervous system, which over sixty years of age people prone to. The pathogenesis is degeneration and death of midbrain substantia nigra dopaminergic neurons, which further leads to the decrease of dopamine content in the striatum. Pimavanserin was a drug developed by Acadia Pharmaceuticals to treat Parkinson's psychiatric symptoms, which is a serotonin 2A receptor (5-HT2A) strongly selective inhibitor. It mainly used for the treatment of Parkinson's psychiatric symptoms such as hallucinations and delusions. In this paper, the chemical properties, pharmacological effect, clinical trials, adverse effects, and other aspects of pimavanserin were reviewed.
[中图分类号]
[基金项目]